Hannan Kathy Hopinkah 4
4 · Ginkgo Bioworks Holdings, Inc. · Filed Jun 14, 2024
Insider Transaction Report
Form 4
Hannan Kathy Hopinkah
Director
Transactions
- Exercise/Conversion
Class A Common Stock
2024-06-12+105,263→ 167,249 total - Exercise/Conversion
Restricted Stock Units
2024-06-12−105,263→ 0 totalExercise: $0.00→ Class A Common Stock (105,263 underlying) - Award
Restricted Stock Units
2024-06-13+432,900→ 432,900 totalExercise: $0.00→ Class A Common Stock (432,900 underlying) - Award
Stock Option
2024-06-13+571,428→ 571,428 totalExercise: $0.46Exp: 2034-06-13→ Class A Common Stock (571,428 underlying)
Footnotes (4)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F2]In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.
- [F3]The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 13, 2025 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date.
- [F4]In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000.